NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of...
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free...
Ponsegromab for the Treatment of Cancer Cachexia
The monoclonal antibody ponsegromab increased weight, improved appetite, and led to increased physical activity in patients with cancer cachexia who had lost weight during...
